SpaceX IPO launches today. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTPH.L Regulatory News (MTPH)

  • There is currently no data for MTPH

Statement regarding Price Movement

1 May 2020 11:08

RNS Number : 6700L
Midatech Pharma PLC
01 May 2020
 

1 May 2020

 

Midatech Pharma PLC

("Midatech" or the "Company")

 

Statement regarding Price Movement

 

 

Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines notes the recent movement in its share price and the Company confirms that it knows of no operational or corporate reason for the share price move.

 

As noted in the Company's recent announcements on 20 April 2020 and 31 March 2020 regarding the Company's strategic review, the Company continues in its Formal Sale Process and confirms that there are no material updates following those announcements.

 

The Company expects to announce its full year results for the year ended 31 December 2019 by the end of June 2020.

 

 

Midatech Pharma PLC

Stephen Stamp, CEO, CFO

Tel: +44 (0)1235 888300

www.midatechpharma.com

Panmure Gordon (UK) Limited (Nominated Adviser and Broker)

Freddy Crossley, Emma Earl (Corporate Finance)

James Stearns (Corporate Broking)

Tel: +44 (0)20 7886 2500

IFC Advisory Limited (Financial PR and UK Investor Relations)

Tim Metcalfe / Graham Herring

Tel: +44 (0)20 3934 6630

Email: midatech@investor-focus.co.uk

Edison Group (US Investor Relations)

Joseph Green/ Laine Yonker

Tel: (646) 653-7030/ 7035

jgreen@edisongroup.com/ lyonker@edisongroup.com

 

 

Publication on website

A copy of this announcement will be made available (subject to certain restrictions relating to persons resident in restricted jurisdictions) on the Company's website at www.midatechpharma.com in accordance with Rule 26.1 of the Code by no later than 12 noon (London time) on 21 April 2020. For the avoidance of doubt, the content of the website referred to in this announcement is not incorporated into and does not form part of this announcement.

Disclosure requirements of the Code

Under Rule 8.3(a) of the Code, any person who is interested in 1% or more of any class of relevant securities of an offeree company or of any securities exchange offeror (being any offeror other than an offeror in respect of which it has been announced that its offer is, or is likely to be, solely in cash) must make an Opening Position Disclosure following the commencement of the offer period and, if later, following the announcement in which any securities exchange offeror is first identified. An Opening Position Disclosure must contain details of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s). An Opening Position Disclosure by a person to whom Rule 8.3(a) applies must be made by no later than 3.30 pm (London time) on the 10th business day following the commencement of the offer period and, if appropriate, by no later than 3.30 pm (London time) on the 10th business day following the announcement in which any securities exchange offeror is first identified. Relevant persons who deal in the relevant securities of the offeree company or of a securities exchange offeror prior to the deadline for making an Opening Position Disclosure must instead make a Dealing Disclosure.

Under Rule 8.3(b) of the Code, any person who is, or becomes, interested in 1% or more of any class of relevant securities of the offeree company or of any securities exchange offeror must make a Dealing Disclosure if the person deals in any relevant securities of the offeree company or of any securities exchange offeror. A Dealing Disclosure must contain details of the dealing concerned and of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s), save to the extent that these details have previously been disclosed under Rule 8. A Dealing Disclosure by a person to whom Rule 8.3(b) applies must be made by no later than 3.30 pm (London time) on the business day following the date of the relevant dealing.

If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire or control an interest in relevant securities of an offeree company or a securities exchange offeror, they will be deemed to be a single person for the purpose of Rule 8.3.

Opening Position Disclosures must also be made by the offeree company and by any offeror and Dealing Disclosures must also be made by the offeree company, by any offeror and by any persons acting in concert with any of them (see Rules 8.1, 8.2 and 8.4).

Details of the offeree and offeror companies in respect of whose relevant securities Opening Position Disclosures and Dealing Disclosures must be made can be found in the Disclosure Table on the Takeover Panel's website at www.thetakeoverpanel.org.uk, including details of the number of relevant securities in issue, when the offer period commenced and when any offeror was first identified. You should contact the Takeover Panel's Market Surveillance Unit on +44 (0)20 7638 0129 if you are in any doubt as to whether you are required to make an Opening Position Disclosure or a Dealing Disclosure.

Additional information

Panmure Gordon (UK) Limited ("Panmure"), is authorised and regulated by the Financial Conduct Authority in the United Kingdom. Panmure is acting as financial adviser in relation to the Takeover Code exclusively for Midatech and no one else in connection with the matters set out in this announcement and will not regard any other person as its client in relation to the matters set out in this announcement and will not be responsible to anyone other than Midatech for providing the protections afforded to clients of Panmure or its affiliates, or for providing advice in relation to the contents of this announcement or any other matter referred to herein.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
SPMSSMFSFESSESI
Date   Source Headline
16th Sep 20215:00 pmRNSOfficial Opening of New Cardiff Headquarters
17th Aug 20215:23 pmRNSChange of Registered Office
15th Jul 202110:28 amRNSGrant of Options and PDMR dealings
12th Jul 20212:30 pmRNSAppointment of Chief Scientific Officer
7th Jul 202111:21 amRNSHolding(s) in Company
30th Jun 202112:07 pmRNSResult of AGM
29th Jun 20217:00 amRNSUK Placing to Raise £10.0 million
18th Jun 20214:29 pmRNSHolding(s) in Company
17th Jun 20214:41 pmRNSSecond Price Monitoring Extn
17th Jun 20214:35 pmRNSPrice Monitoring Extension
17th Jun 20212:05 pmRNSSecond Price Monitoring Extn
17th Jun 20212:00 pmRNSPrice Monitoring Extension
17th Jun 202111:00 amRNSPrice Monitoring Extension
17th Jun 20217:00 amRNSBreakthrough data using Q-Sphera technology
9th Jun 20217:00 amRNSInvestor Webinar Scheduled for 17 June 2021
21st May 20213:56 pmRNSPosting of Annual Report & Notice of AGM
30th Apr 20212:05 pmRNSResults for the Year Ended 31 December 2020
25th Mar 20217:00 amRNSMTX110 Update & Headline Results for 2020
17th Feb 20217:00 amRNSExercise of Warrants and Issue of Equity
16th Feb 20215:46 pmRNSHolding(s) in Company
15th Feb 20214:12 pmRNSHolding(s) in Company
11th Feb 20216:20 pmRNSHolding(s) in Company - Replacement
11th Feb 20213:42 pmRNSHolding(s) in Company
5th Feb 20219:05 amRNSSecond Price Monitoring Extn
5th Feb 20219:00 amRNSPrice Monitoring Extension
26th Jan 20212:06 pmRNSSecond Price Monitoring Extn
26th Jan 20212:01 pmRNSPrice Monitoring Extension
26th Jan 202110:30 amRNSBusiness Update
8th Jan 20214:40 pmRNSSecond Price Monitoring Extn
8th Jan 20214:36 pmRNSPrice Monitoring Extension
11th Dec 20205:00 pmRNSMTX110 Programmes to be presented at ISPNO 2020
11th Dec 202010:00 amRNSLaunch of new website
9th Dec 20207:00 amRNSParliament Highlights Need for New DIPG Treatments
24th Nov 20207:00 amRNSMTX110 presented at 2020 Annual SNO Conference
19th Oct 20204:40 pmRNSSecond Price Monitoring Extn
19th Oct 20204:35 pmRNSPrice Monitoring Extension
19th Oct 202011:06 amRNSSecond Price Monitoring Extn
19th Oct 202011:00 amRNSPrice Monitoring Extension
19th Oct 20207:00 amRNSHeadline Results of MTX110 Phase I DIPG Study
30th Sep 20205:54 pmRNSIssue of Equity for Employee Share Incentive Plan
23rd Sep 202011:42 amRNSHolding(s) in Company
16th Sep 20207:00 amRNSHolding(s) in Company
10th Sep 20207:00 amRNSInterim results - 6 months ended 30 June 2020
7th Sep 20207:00 amRNSInvestor Webinar
28th Aug 20207:00 amRNSNotice of Interim Results
25th Aug 20202:51 pmRNSHolding(s) in Company
21st Aug 20202:06 pmRNSSecond Price Monitoring Extn
21st Aug 20202:00 pmRNSPrice Monitoring Extension
19th Aug 20207:00 amRNSExercise of Warrants and Issue of Equity
17th Aug 20205:42 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.